Erbitux, a metastatic rectal and colon cancer therapy, successfully renewed the RSA agreement. This is the first case which renewed the agreement through a renegotiation.
According to the National Health Insurance Service(NHIS) on the 14th, Merck and the NHIS have concluded the RSA revaluation agreement this early month.
The term of the renewal is 4 years.
Erbitux 5mg/ml(cetuximab), a Merck’...